News & Investors

Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Cara Therapeutics Announces Successful Completion of Phase I Clinical Trial of Novel Analgesic, CR845
Cara Therapeutics Announces Successful Completion of Phase I Clinical Trial of Novel Analgesic, CR845 Cara Therapeutics, Inc. today announced completion of a Phase I clinical trial for its second-generation, peripherally acting kappa opioid agonist, CR845, under development for the treatment of
View HTML
Toggle Summary Cara Therapeutics Secures $12.3 Million In Series C Extension Financing
Cara Therapeutics Secures $12.3 Million In Series C Extension Financing Cara Therapeutics, Inc. announced today that it had closed on $12.3 million of additional funding to its original $24 million Series C financing which was completed in 2007. The round was led by new investor, Devon Park
View HTML
Toggle Summary Cara Therapeutics Announces Issuance of U.S. Patent Covering Second Generation Kappa Opioid Receptor Agonists
Cara Therapeutics Announces Issuance of U.S. Patent Covering Second Generation Kappa Opioid Receptor Agonists Cara Therapeutics, Inc. announced today that The United States Patent and Trademark Office has issued U.S. Patent No. 7,402,564 entitled “Synthetic Peptide Amides” under its Accelerated
View HTML
Toggle Summary Synthesis, SAR Evaluation and Molecular Modeling of Modified Phenanthridines: Novel and Selective CB2 Agonists" View HTML
Toggle Summary Cara Therapeutics Initiates Phase 1 Clinical Trial of Novel Analgesic, CR845
Cara Therapeutics Initiates Phase 1 Clinical Trial of Novel Analgesic, CR845 Cara Therapeutics, Inc. today announced that it has initiated a Phase 1 clinical trial of its long-acting peripheral kappa opioid receptor agonist, CR845. The Phase 1a single-center clinical trial will evaluate the safety,
View HTML
Toggle Summary Cara Therapeutics Secures $19 Million In Series C Financing
Cara Therapeutics Secures $19 Million In Series C Financing Cara Therapeutics, Inc. announced today that it had closed on $19 million of its Series C financing. New investors participating in the round include MVM Life Science Partners and Alta Biopharma Partners, as well as previous investors
View HTML
Toggle Summary Tripos and Cara Therapeutics Announce Medicinal Chemistry Partnership; Alliance to Address Unmet Medical Needs in the Treatment of Pain and Inflammation
Tripos and Cara Therapeutics Announce Medicinal Chemistry Partnership; Alliance to Address Unmet Medical Needs in the Treatment of Pain and Inflammation Tripos, Inc. (Nasdaq:TRPS), a leading provider of drug discovery chemistry and informatics products and services, today announced that Tripos
View HTML
Toggle Summary Cara Therapeutics Announces Results of Phase 1 Clinical Trial of Novel Analgesic
Cara Therapeutics Announces Results of Phase 1 Clinical Trial of Novel Analgesic Cara Therapeutics, Inc. today announced results of a Phase 1 clinical trial for its peripherally acting kappa opioid agonist, CR665, under development for the treatment of postoperative pain.
View HTML
Toggle Summary Cara Therapeutics Initiates Clinical Trial of Novel Pain Drug Candidate
Cara Therapeutics Initiates Clinical Trial of Novel Pain Drug Candidate Cara Therapeutics, Inc. announced today that it had initiated dosing in a Phase 1 clinical trial for CR665, its novel drug candidate for the treatment of postoperative pain. The single-dose protocol is scheduled to be completed
View HTML